The bill requires the Executive Office of Health and Human Services to submit a quarterly report detailing the projected total costs for pharmaceutical pipeline drugs anticipated to be available for use within the next fiscal year. Specifically, it focuses on drugs identified by the executive office that are expected to be utilized between April 1, 2025, and March 31, 2026. The report will include an estimated spending figure, which is projected to be approximately $19.5 million for all MassHealth members, including those enrolled in managed care. This figure reflects an increase from a prior estimate of $20 million based on 64 pipeline market entries.

Additionally, the report highlights that high-cost cell and gene therapies are significant contributors to the overall spending. The bill emphasizes the importance of transparency and accountability in managing pharmaceutical costs within the state's healthcare system. For any inquiries regarding the report, contact information for Sarah Nordberg-Dunlea is provided, indicating a direct line for further clarification or questions.